El desarrollo de estos nuevos antiarrítmicos supondría una disrupción en un área en la que, desde hace más de tres décadas, no se han desarrollado fármacos alternativos a los comercializados qu...
Read moreThe funding will drive two preclinical development programs for its groundbreaking drug, ACT-02—an innovative compound with potential disease-modifying properties. ACT-02 functions as an inhibitor o...
Read moreFrom this new headquarters, Funditec Health, led by Dr. Domingo Gargallo-Viola, will continue its work in translational research, therapeutic development, and health innovation, heading both national ...
Read moreOryzon Genomics announced today that the first patient has been dosed in a Phase I/II trial of iadademstat, Oryzon’s potent and selective LSD1 inhibitor, in combination with immune checkpoint inhibi...
Read moreNature, the world's leading scientific journal, has spotlighted three Barcelona-based biotech startups, Ona Therapeutics, Nuage Therapeutics, and SpliceBio, in a recent article highlighting Spain's bu...
Read moreThe patent, titled “Methods of treating Attention Deficit Hyperactivity Disorder using KDM1A inhibitors such as the compound vafidemstat”, covers the use Oryzon’s LSD1 inhibitor, vafidemstat, cu...
Read moreIt has been announced today the successful completion of a €30 million capital increase through the issuance of 12,765,958 new shares, priced at €2.35 per share. This pricing reflects a 15.44%
Read moreEnhanced platform technology and the addition of a robust, high-quality CHO K-1 cell line decreases lead time to Investigational New Drug (IND)
Read moreFounded in 2022 as a spin-off from Vall d'Hebron Institut d'Oncologia, the University of Barcelona and Icrea, Oniria Therapeutics specialises in the development of targeted therapies to eliminate pers...
Read moreUn estudio colaborativo publicado recientemente en la revista British Journal of Pharmacology, ha mostrado la capacidad de la molécula MP-010, desarrollada por la spinoff del IIS Biogipuzkoa Miramoon...
Read moreOryzon to validate epigenetic agents by applying a personalized medicine approach for rare and orphan diseases
Read more